Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a strategic research collaboration and worldwide license agreement with Biontech SE for the development of a next-generation antibody-drug conjugate candidate (ADC) against HER3.

Immetas Therapeutics Inc. and GC Biopharma Corp. have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases. The collaboration combines Immetas’ proprietary platform for modulating innate immune pathways with GC Biopharma’s mRNA therapeutic and lipid nanoparticle (LNP) delivery platforms.

Imidomics Inc. has entered into a strategic license and collaboration agreement with the University of Barcelona under which Imidomics has licensed technology and expertise to advance research aimed at understanding and treating immune-mediated inflammatory diseases.

Stem Pharm Inc. and Verge Genomics (Verge Analytics Inc.) have established a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease.

Sparx Group has formed a strategic alliance with Arovella Therapeutics Ltd. for the development of a CLDN18.2-chimeric antigen receptor (CAR)-invariant natural killer T (iNKT) cell therapy.

Salipro Biotech AB and Icosagen AS have entered into a multitarget antibody research agreement for the discovery and characterization of monoclonal antibodies against several challenging membrane proteins.

Biomap (Beijing) Intelligent Technology Co Ltd. has entered into a strategic collaboration with Sanofi SA to co-develop cutting-edge artificial intelligence (AI) modules for biotherapeutic drug discovery by leveraging Biomap’s AI platform.

Circio Holding ASA and Neoregen Biotech have commenced a research collaboration on novel circular RNA (circRNA) therapeutics based on Circio’s proprietary Circvec technology. The technology is composed of a modular genetic cassette design for efficient biogenesis of multifunctional circRNAs that can be adapted and applied to multiple purposes.